# EDGAR Filing Document

**Accession Number:** 0001862005
**File Stem:** 0001104659-23-031804
**Filing Date:** 2023-3
**Character Count:** 8608
**Document Hash:** a5eb983957cf868745e9bf7cf5ba5745
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-031804.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001104659-23-031804

**CONFORMED SUBMISSION TYPE**: 8-A12B

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASTRAZENECA PLC
- **CENTRAL INDEX KEY:** 0000901832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-A12B
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11960
- **FILM NUMBER:** 23727798

**BUSINESS ADDRESS:**
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB2 0AA
- **BUSINESS PHONE:** 011 44 20 7304 5000

**MAIL ADDRESS:**
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB2 0AA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZENECA GROUP PLC
- **DATE OF NAME CHANGE:** 19930422
**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AstraZeneca Finance LLC
- **CENTRAL INDEX KEY:** 0001862005
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 8-A12B
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40452
- **FILM NUMBER:** 23727799

**BUSINESS ADDRESS:**
- **STREET 1:** 1209 ORANGE STREET
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** 1-800-677-3394

**MAIL ADDRESS:**
- **STREET 1:** 1209 ORANGE STREET
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**<br> **WASHINGTON, D.C. 20549**

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES<br> PURSUANT TO SECTION 12(b) OR (g) OF THE<br> SECURITIES EXCHANGE ACT OF 1934**

**AstraZeneca PLC**<br> (Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **England and Wales**<br> (State or other jurisdiction of incorporation or<br> organization) | **Not Applicable**<br> (I.R.S. Employer<br> Identification No.) |
| **1 Francis Crick Avenue<br> Cambridge Biomedical Campus<br> Cambridge, United Kingdom**<br> (Address of principal executive offices) | **CB2 0AA**<br> (Zip Code) |

---

**AstraZeneca Finance LLC**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware**<br> (State or other jurisdiction of incorporation or <br> organization) | **86-3730535**<br> (I.R.S. Employer<br> Identification No.) |
| **1209 Orange Street**<br> **Wilmington, Delaware**<br> **United States of America**<br> (Address of principal executive offices) | **19801**<br> (Zip Code) |

---

**Securities to be registered pursuant to Section 12(b) of the Act:**

---

| | |
|:---|:---|
| **Title of each class<br> to be so registered**  | **Name of each exchange on which<br> each class is to be registered**  |
| 4.875% Notes due 2028 (and the guarantee of AstraZeneca PLC related thereto) | The Nasdaq Stock Market LLC |
| 4.900% Notes due 2030 (and the guarantee of AstraZeneca PLC related thereto) | The Nasdaq Stock Market LLC |
| 4.875% Notes due 2033 (and the guarantee of AstraZeneca PLC related thereto) | The Nasdaq Stock Market LLC |

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ⌧

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ◻

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ◻

Securities Act registration statement or Regulation A offering statement file number to which this form relates: **Not applicable.**

Securities to be registered pursuant to Section 12(g) of the Act: **None.**

**INFORMATION REQUIRED IN REGISTRATION STATEMENT**

AstraZeneca PLC ("AstraZeneca") and AstraZeneca Finance LLC ("AstraZeneca Finance" and, together with AstraZeneca, the "Registrants") filed with the Securities and Exchange Commission (the "Commission") pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the "Securities Act"), a prospectus supplement, dated February 28, 2023 (the "Prospectus Supplement"), and the accompanying prospectus, dated May 24, 2021 (the "Prospectus"). The Prospectus Supplement relates to the offering of $1,100,000,000 4.875% Notes due 2028, $650,000,000 4.900% Notes due 2030 and $500,000,000 4.875% Notes due 2033 issued by AstraZeneca Finance and fully and unconditionally guaranteed by AstraZeneca. The Prospectus forms a part of the Registrants' Registration Statement on Form F-3 (File No. 333-256406) filed with the Commission on May 24, 2021. The Prospectus Supplement and the Prospectus are incorporated herein by reference to the extent set forth below.

**Item 1. Description of Registrant's Securities to Be Registered.**

Reference is made to the information set forth under the headings "Description of Debt Securities and Guarantees" on pages 14 through 30 and "Certain UK and U.S. Federal Tax Considerations" on pages 35 through 43 of the Prospectus; and to the information set forth under the headings "Description of Notes" on pages S-12 through S-17 and "Taxation" on page S-18 of the Prospectus Supplement, which information is incorporated herein by reference.

**Item 2. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| [<u>1.1</u>](https://www.sec.gov/Archives/edgar/data/901832/000110465921070823/tm2116866-1_f3asr.htm) | [<u>Registration Statement on Form F-3, including the Prospectus (incorporated herein by reference to the Registration Statement on Form F-3 filed with the Commission by AstraZeneca PLC and AstraZeneca Finance LLC on May 24, 2021 (File No. 333-256406)).</u>](https://www.sec.gov/Archives/edgar/data/901832/000110465921070823/tm2116866-1_f3asr.htm) |
| [<u>1.2</u>](https://www.sec.gov/Archives/edgar/data/901832/000110465923027978/tm237224-6_424b2.htm) | [<u>Prospectus Supplement (incorporated herein by reference to the prospectus filed with the Commission by AstraZeneca PLC and AstraZeneca Finance LLC on March 2, 2023 pursuant to Rule 424(b2)).</u>](https://www.sec.gov/Archives/edgar/data/901832/000110465923027978/tm237224-6_424b2.htm) |
| [<u>4.1</u>](https://www.sec.gov/Archives/edgar/data/901832/000110465921074174/tm2116866d11_ex4-2.htm) | [<u>Indenture, dated as of May 28, 2021, among AstraZeneca Finance LLC, as issuer, AstraZeneca PLC, as guarantor, and The Bank of New York, as trustee (incorporated by reference to Exhibit 4.2 to the foreign private issuer report on Form 6-K filed with the Commission by AstraZeneca PLC on May 28, 2021).</u>](https://www.sec.gov/Archives/edgar/data/901832/000110465921074174/tm2116866d11_ex4-2.htm) |
| [<u>4.2</u>](https://www.sec.gov/Archives/edgar/data/901832/000110465923028456/tm237224d8_ex4-1.htm) | [<u>Officers' Certificate pursuant to Section 2.08 of the Indenture setting forth the terms of the AstraZeneca Finance securities, including forms of the global notes for the 4.875% Notes due 2028, the 4.900% Notes due 2030 and the 4.875% Notes due 2033 (incorporated by reference to Exhibit 4.1 to the foreign private issuer report on Form 6-K filed with the Commission by AstraZeneca PLC on March 3, 2023).</u>](https://www.sec.gov/Archives/edgar/data/901832/000110465923028456/tm237224d8_ex4-1.htm) |

---

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, each Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Dated: March 13, 2023 | **AstraZeneca PLC** | **AstraZeneca PLC** | **AstraZeneca PLC** |
|  | (Registrant) | (Registrant) | (Registrant) |
|  | By: | /s/ Jonathan Slade | /s/ Jonathan Slade |
|  |  | Name: | Jonathan Slade |
|  |  | Title: | Group Treasurer |

---

---

| | | |
|:---|:---|:---|
| **AstraZeneca Finance LLC** | **AstraZeneca Finance LLC** | **AstraZeneca Finance LLC** |
| (Registrant) | (Registrant) | (Registrant) |
| By: | /s/ David E. White | /s/ David E. White |
|  | Name: | David E. White |
|  | Title: | President, Treasurer and Director |

---